In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...

Last year, DeepMind’s AlphaFold2 AI system made a “significant contribution to humanity’s understanding of biology.” Alphabet has now taken that advancement and created a new company called Isomorphic ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...

Last year, DeepMind produced a stunning advance in scientific research, demonstrating how its artificial intelligence could be used to predict 3D structures of unique proteins in a solution to a ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design and ...

The company will build off of breakthroughs in protein prediction from DeepMind and inches Big Tech one step further into the healthcare industry. Reading time 2 minutes Alphabet has spun off a new ...

The field of drug discovery has been supercharged by the capabilities of AI, which several companies have applied in various ways to turn an enormous practical problem into a tractable information ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...